Peptides and mood: the evidence, and why most people never see it

TL;DR

• Selank completed Phase III trials for generalised anxiety disorder - and is approved in Russia for GAD and neurasthenia. Most Western readers have never heard this.
• It was compared head-to-head against a benzodiazepine (phenazepam) in anxiety, and is reported not to produce physical dependence - the contrast that makes the comparison interesting.
• Semax is an ACTH(4-10) analogue acting through BDNF, with BDNF and trkB upregulation shown repeatedly; in a trial of 110 stroke patients it raised plasma BDNF.
• The honest gap: the human trials were run in stroke, encephalopathy and optic nerve disease - not in healthy adults wanting steadier mood. That extrapolation is the real weakness.
• There are no large Western RCTs, and the reason is economic - these are old, off-patent sequences no sponsor can recoup a trial on. Absence of a Western trial is not a verdict on the molecule.
• Mood is a clinical domain first. Depression and anxiety have effective treatments. Nothing here substitutes for them.

Educational content, not medical advice. No doses or protocols appear. Peptide therapy is physician-directed.

---

Before anything else

Depression and anxiety are real medical conditions with real, effective treatments. If your mood has been persistently low, if you have lost interest in things you used to care about, if it is affecting your work or relationships, or if it has lasted more than a couple of weeks - that is a clinical conversation, and it is a more useful one than anything on this page.

Nothing described here is a treatment for a mood disorder, and nothing here should delay you getting one.

If you are having thoughts of harming yourself, please talk to someone now - in the US, call or text 988 (Suicide & Crisis Lifeline). In Malaysia, Befrienders KL operate a 24-hour line. Elsewhere, your local emergency number or a nearby hospital. This is not a footnote and it is not a formality.

With that stated plainly, here is what the evidence actually contains - because there is considerably more of it than the usual "no good data" summary suggests, and the reason you haven't seen it is interesting in itself.

The thing almost nobody in this conversation knows

Selank has completed Phase III clinical trials.

Not preclinical work. Not a mechanistic paper. Phase III trials, in generalised anxiety disorder - and it is approved in Russia for GAD and neurasthenia. It has also been studied in direct comparison against phenazepam, a benzodiazepine, in anxiety disorders, and is reported within that literature not to produce physical dependence.

Sit with that for a second, because it reframes the whole category. A peptide in the "nootropic" bucket that most Western readers file next to unregulated supplements has a national regulatory approval for an anxiety indication and a comparative trial against the drug class it would be replacing.

Semax has a similar shape. It is an ACTH(4-10) analogue, and its proposed mechanism is unusually well characterised for this space: upregulation of BDNF and its receptor trkB - brain-derived neurotrophic factor, the signalling molecule most consistently implicated in how the brain maintains and remodels connections. That upregulation has been demonstrated repeatedly, though largely in animal models. In a human trial of 110 stroke patients, intranasal Semax increased plasma BDNF levels.

Selank is a tuftsin analogue, with described effects on GABAergic and serotonergic signalling alongside the BDNF pathway. In animal models, Semax normalised disrupted behaviour caused by anxiety-inducing compounds.

Now the honest part

That evidence is real, and it is also not what most people reading this page want it to be. Three limits, stated plainly.

The indications don't match. Semax's human trials were run mainly in acute ischaemic stroke, encephalopathy and optic nerve disease - at Russian centres, in patients with significant neurological pathology. "Improves outcomes after a stroke" and "makes a healthy adult feel steadier" are different claims about different populations. Extrapolating across that gap is the weakest link in the whole argument, and anyone who glosses over it is selling you something.

The literature is hard to evaluate. Published English-language studies with well-conducted, transparently reported methodology are limited. Much of the underlying work sits in Russian-language journals with different reporting conventions, limited access, and - for most readers and most reviewers - a language barrier that makes independent assessment genuinely difficult. That is a real problem with the evidence, not a slur on it.

There are no large Western RCTs in mood. For either compound. Not thin ones. None.

Why the West never ran the trial

Here is the part that changes how you should read all of the above.

The usual inference from "no Western RCT" is that the compound was tested and found wanting, or that serious researchers looked and weren't interested. Neither is what happened.

Semax and Selank are short, old, off-patent peptide sequences. Nobody owns them. A Western sponsor contemplating a confirmatory Phase III in generalised anxiety would be funding an enormous, multi-year, multi-site trial - and publishing a result that every competitor could use the following morning. There is no exclusivity to recoup it against, so the trial does not get commissioned. It isn't a scientific judgement. It's a spreadsheet.

The Russian work exists because it was done inside a different research and funding system, one where a state institute could carry a compound through development without needing a patent position to justify it.

So the accurate summary is not "there's no evidence." It's: there is a clinical literature, it was produced under a system that doesn't map onto Western regulatory expectations, and no one has the commercial incentive to redo it in a form the West would accept. That is a fact about the pharmaceutical economy. It is not a finding about the molecules.

Which cuts both ways, and I want to be even-handed about that: the absence of independent Western replication is a genuine reason for caution, not just an artefact to be explained away. Unreplicated is unreplicated, whatever the reason.

The adjacent threads worth watching

The gut–brain axis. The literature connecting intestinal barrier integrity, systemic inflammation and mood has grown substantially and is taken seriously in mainstream psychiatry research. That makes gut-acting compounds like KPV and BPC-157 mechanistically interesting for mood - as a hypothesis, through an inflammatory pathway, not as a demonstrated treatment. Nobody has run the mood trial. See BPC-157 and KPV for gut healing for what that evidence does and doesn't cover.

GLP-1s and mood. Effects have been reported in both directions, regulators have looked at the signals, and no causal link has been established at population level. We cover that specifically in motivation loss on a GLP-1 and don't restate it here.

Community-reported patterns. People self-report effects from these compounds constantly, and it is worth being precise about what that is worth. A single enthusiastic report is worth approximately nothing - expectancy effects are powerful, and mood is among the most suggestible outcomes there is. What makes a reported pattern more interesting is consistency across many independent reports, a plausible time-course, and a relationship to exposure. Even then it is a hypothesis generator, not evidence. It tells you what would be worth testing, not what is true. How to read what a study actually measured applies to anecdote too.

Where this sits in a sensible order

Mood is the domain where getting the order right matters most, because the foundations are unusually powerful here and unusually easy to skip.

First, the base. Sleep is not a lifestyle garnish in mood - it is one of the most reliable levers that exists, and disrupted sleep both causes and worsens low mood. Training has genuine antidepressant effect sizes in controlled trials. Alcohol, light exposure and social contact all move this more than most people credit. See sleep optimisation foundations.

Second, measure. Thyroid dysfunction, iron deficiency, low vitamin D, B12 and disordered glucose regulation all present as mood symptoms and all are correctable. This is the step that gets skipped, and it is the one most likely to find something real. Peptide therapy biomarkers covers what a baseline panel reasonably includes.

Third, and only then, consider what else might help - with a clinician, with the evidence limits above stated honestly, and with an actual plan for deciding whether it is working. Selank and Semax are investigational compounds, not casual experiments, and mood is precisely the domain where an outside observer, such as your own doctor, matters - because you are the least reliable judge of your own mood trajectory.

If a proper assessment finds a mood disorder, treat the mood disorder. That is not the consolation prize. That is the intervention with the best evidence in this entire article.

Frequently asked questions

Is there real evidence peptides help mood? For Selank, yes in a specific and qualified sense - completed Phase III trials and a national approval for generalised anxiety disorder, in Russia. For Semax, a well-characterised BDNF mechanism and human trials in neurological conditions rather than mood. For healthy adults seeking better mood specifically, the direct evidence is thin, and the honest framing is unestablished rather than disproven.

If Selank is approved for anxiety, why isn't it available here? Approval is jurisdictional. A Russian approval is not an FDA or regional approval, and no sponsor has taken the compound through Western review - largely because there is no patent position to make that economically rational. Filed, approved and available are three different things.

Can these replace an antidepressant or anti-anxiety medication? No, and nothing here should be read that way. If you are on treatment, do not change it based on an article. If you are considering stopping something, that decision belongs with the prescriber who started it.

What would actually settle this? A pre-registered, adequately powered, independent randomised trial in the population people actually want to use these in - healthy or subclinical adults, mood as the primary endpoint, long enough to matter. It does not exist for either compound, and the funding structure described above is the reason.

Related reading

• Semax and Selank: the nootropic peptides - the compound-level detail
• Brain fog is not one problem - the differential worth working through first
• Peptides and the blood-brain barrier - what can actually reach the brain
• Is Semax legal in 2026? · Motivation loss on a GLP-1
• What a study actually measured · What 565 studies found about six popular peptides
• Part of Nootropic Peptides

Mood is the domain where an outside observer matters most. Vivre Labs recommends baseline bloodwork that screens the correctable causes first, and frames honestly what the evidence does and doesn't support; when the answer is a psychiatrist rather than a compound, your own doctor is the right person to make that referral. Where something is appropriate, it sits in the V-02 Focus protocol. Book a consult - Telegram.

---

Educational content, not medical advice. This page describes published research and regulatory status in named jurisdictions; it does not claim that any peptide treats depression, anxiety or any mood disorder. Selank's approval is specific to Russia and is not an approval in the US, EU or Malaysia. Semax and Selank are not approved for mood indications in Western markets. Depression and anxiety are medical conditions requiring clinical assessment. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 15 September 2026.

References

• Selank: completed Phase III clinical trials in Russia for generalised anxiety disorder; approved in Russia for GAD and neurasthenia; comparative trial against phenazepam (benzodiazepine) in anxiety disorders; reported within that literature not to produce physical dependence. Tuftsin analogue; described effects on GABAergic and serotonergic signalling and on BDNF.
• Semax: ACTH(4-10) analogue; BDNF and trkB upregulation demonstrated repeatedly, largely in animal models; human trial in 110 stroke patients reported increased plasma BDNF following intranasal administration. Human trials conducted mainly in acute ischaemic stroke, encephalopathy and optic nerve disease, almost all at Russian centres. In animal models, normalised disrupted behaviour induced by anxiogenic compounds.
• Evidence limits: well-conducted English-language studies are limited; no large Western randomised controlled trials in mood for either compound; studied indications differ materially from healthy-adult mood support.
• Trial economics: both are off-patent, publicly described sequences without an exclusivity position; commercial sponsors fund pivotal trials they expect to recoup through exclusivity, which is the structural reason no Western confirmatory trial has been commissioned.
• Crisis support: 988 Suicide & Crisis Lifeline (US); Befrienders KL (Malaysia, 24-hour).

Reviewer note: the Semax stroke-trial dose appears in the source literature and has been deliberately omitted here in line with the no-dosing standard. Do not add it. Selank's Russian approval is stated as a jurisdictional fact and must not be rewritten into an efficacy claim.